Results 21 to 30 of about 27,341 (230)

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. [PDF]

Clin Cardiol
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Sajid EU, Azeem MH, Fatima A, Jafri SM, Hassan D, Ibrahim T, Manjee KZ, Ahmed SR, Ali T, Shakeel R, Usman M, Mahato RK, Bawa D.   +12 more
europepmc   +2 more sources

Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis

Journal of Medicine and Life, 2023
Ulcerative colitis is a chronic inflammatory disease with high mortality and morbidity worldwide. It causes inflammation in the lining of the colon, resulting in several symptoms that negatively impact the quality of life.
F. R. Jaafar, Ahmed R. Abu-raghif
semanticscholar   +1 more source

Ezetimibe Induces Paraptosis through Niemann–Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells

Genes, 2023
Currently, hepatocellular carcinoma (HCC) is characterized by its unfavorable prognosis and resistance to conventional chemotherapy and radiotherapy. Drug repositioning, an approach aimed at identifying novel therapeutic applications for existing drugs ...
Yuting Yin, Chun Wu, Yufeng Zhou, Mei-yin Zhang, Shijuan Mai, Minshan Chen, Hui-Yun Wang   +6 more
semanticscholar   +1 more source

Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Medicina, 2023
Background and Objectives: Lipid-lowering agents such as ezetimibe are recommended in uncontrolled hyperlipidemia for primary and secondary prevention of cardiovascular disease.
Ryuk Jun Kwon, Young Hye Cho, Eun Ju Park, Youngin Lee, Sae Rom Lee, Jung In Choi, Sang Yeoup Lee, Soo Min Son   +7 more
doaj   +1 more source

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

BMC Medicine, 2022
The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of ezetimibe plus rosuvastatin versus rosuvastatin monotherapy to reduce liver fat using magnetic ...
Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-wan Lee, E. Kang, B. Cha, Jin-Young Choi, Yong‐ho Lee   +8 more
semanticscholar   +1 more source

Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.

European Heart Journal, 2022
AIMS This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy vs. high-intensity statin monotherapy among patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD).
Yong-Joon Lee, J. Cho, S. You, Yong-ho Lee, K. Yun, Yun‐Hyeong Cho, Won-Yong Shin, Sang Wook Im, W. Kang, Yongwhi Park, Sung Yoon Lee, Seung-Jun Lee, Sung‐Jin Hong, C. Ahn, Byeong‐Keuk Kim, Y. Ko, D. Choi, M. Hong, Y. Jang, Jung‐Sun Kim   +19 more
semanticscholar   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway

Heliyon, 2023
Cholesterol levels were strongly associated with tumor progression and metastasis. Targeted cholesterol metabolism has broad prospects in tumor treatment.
Qinyu He, Lingkai Kong, Weiwei Shi, Ding Ma, Kua Liu, Shuwei Yang, Qilei Xin, Chunping Jiang, Junhua Wu   +8 more
doaj   +1 more source

PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations

British medical journal, 2022
Clinical question In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein ...
Q. Hao, B. Aertgeerts, G. Guyatt, G. Bekkering, P. Vandvik, Safi U. Khan, N. Rodondi, R. Jackson, J. Reny, Lubna Al Ansary, M. V. van Driel, W. Assendelft, T. Agoritsas, F. Spencer, R. Siemieniuk, L. Lytvyn, A. Heen, Qian Zhao, I. Riaz, D. Ramaekers, P. Okwen, Ye Zhu, Annabel Dawson, Mersa Caius Ovidiu, Willy Vanbrabant, Sheyu Li, N. Delvaux   +26 more
semanticscholar   +1 more source

Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies

BMJ Medicine, 2022
Objective To determine the harms of ezetimibe in people who need lipid-lowering treatment. Design Systematic review and meta-analysis. Data sources Randomised controlled trials and cohort studies.
Yang Wang, Shi Zhan, Heyue Du, Jing Li, Safi U. Khan, B. Aertgeerts, G. Guyatt, Q. Hao, G. Bekkering, Ling Li, N. Delvaux, N. Su, I. Riaz, P. Vandvik, H. Tian, Sheyu Li   +15 more
semanticscholar   +1 more source